Global Emergency Contraceptive Pill Market 2018-2022
出 版 商：Technavio
出版日期：2018/07/18
頁 數：104頁
文件格式：PDF
價 格：
USD 2,500 (Single-User License)
USD 3,000 (Multi-User License)
USD 4,000 (Global-User License)
USD 3,000 (Multi-User License)
USD 4,000 (Global-User License)
About Emergency Contraceptive Pill
An emergency contraceptive pill is a short-term method of contraception that needs to be consumed within 72 hours of unprotected sexual intercourse, sexual assault, lapse in taking birth control pills, or condom breakage to prevent an unplanned pregnancy.
Technavio’s analysts forecast the Global Emergency Contraceptive Pill Market to grow at a CAGR of 2.55% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the emergency contraceptive pill market. To calculate the market size, the report considers the revenue generated from the sales of emergency contraceptive pill.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, emergency contraceptive pill market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ LUPIN
‧ Mankind Pharma
‧ Perrigo
‧ Piramal Enterprises
‧ Sun Pharmaceutical Industries
Market driver
‧ Rise in the number of initiatives to create awareness
‧ For a full, detailed list, view our report
Market challenge
‧ Local governments limiting access to emergency contraceptive pills
‧ For a full, detailed list, view our report
Market trend
‧ Advent of online apps
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2022 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
An emergency contraceptive pill is a short-term method of contraception that needs to be consumed within 72 hours of unprotected sexual intercourse, sexual assault, lapse in taking birth control pills, or condom breakage to prevent an unplanned pregnancy.
Technavio’s analysts forecast the Global Emergency Contraceptive Pill Market to grow at a CAGR of 2.55% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the emergency contraceptive pill market. To calculate the market size, the report considers the revenue generated from the sales of emergency contraceptive pill.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, emergency contraceptive pill market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ LUPIN
‧ Mankind Pharma
‧ Perrigo
‧ Piramal Enterprises
‧ Sun Pharmaceutical Industries
Market driver
‧ Rise in the number of initiatives to create awareness
‧ For a full, detailed list, view our report
Market challenge
‧ Local governments limiting access to emergency contraceptive pills
‧ For a full, detailed list, view our report
Market trend
‧ Advent of online apps
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2022 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
‧ Market ecosystem
‧ Market characteristics
‧ Market segmentation analysis
PART 05: MARKET SIZING
‧ Market definition
‧ Market sizing 2017
‧ Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
‧ Bargaining power of buyers
‧ Bargaining power of suppliers
‧ Threat of new entrants
‧ Threat of substitutes
‧ Threat of rivalry
‧ Market condition
PART 07: MARKET SEGMENTATION BY DISTRIBUTION CHANNEL
‧ Segmentation by distribution channel
‧ Comparison by distribution channel
‧ Retail stores
‧ Online stores
‧ Market opportunity by distribution channel
PART 08: CUSTOMER LANDSCAPE
PART 09: REGIONAL LANDSCAPE
‧ Geographical segmentation
‧ Regional comparison
‧ Americas– Market size and forecast 2017-2022
‧ EMEA – Market size and forecast 2017-2022
‧ APAC – Market size and forecast 2017-2022
‧ Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
‧ Market drivers
‧ Market challenges
PART 12: MARKET TRENDS
‧ Importance of family planning
‧ Advent of online apps
‧ Rising disposable income
PART 13: VENDOR LANDSCAPE
‧ Overview
‧ Landscape disruption
PART 14: VENDOR ANALYSIS
‧ Vendors covered
‧ Vendor classification
‧ Market positioning of vendors
‧ LUPIN
‧ Mankind Pharma
‧ Perrigo
‧ Piramal Enterprises
‧ Sun Pharmaceutical Industries
PART 15: APPENDIX
‧ List of abbreviations
?
Exhibit 01: Parent market
Exhibit 02: Global female contraceptive market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global emergency contraceptive pill 2017-2022 ($ mn)
Exhibit 09: Global emergency contraceptive pill market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Global emergency contraceptive pill market by distribution channel – Market share 2017-2022 (%)
Exhibit 19: Comparison by distribution channel
Exhibit 20: Retail stores – Market size and forecast 2017-2022 ($ mn)
Exhibit 21: Retail stores – Year-over-year growth 2018-2022 (%)
Exhibit 22: Online stores – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Online stores – Year-over-year growth 2018-2022 (%)
Exhibit 24: Market opportunity by distribution channel
Exhibit 25: Customer landscape
Exhibit 26: Global emergency contraceptive pill market by geography – Market share 2017-2022 (%)
Exhibit 27: Regional comparison
Exhibit 28: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 30: Top three countries in Americas
Exhibit 31: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 32: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 33: Top three countries in EMEA
Exhibit 34: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 35: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 36: Top three countries in APAC
Exhibit 37: Market opportunity
Exhibit 38: Vendor landscape
Exhibit 39: Landscape disruption
Exhibit 40: Vendors covered
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: LUPIN overview
Exhibit 44: LUPIN – Business segments
Exhibit 45: LUPIN– Organizational developments
Exhibit 46: LUPIN– Geographic focus
Exhibit 47: LUPIN – Key offerings
Exhibit 48: Mankind Pharma overview
Exhibit 49: Mankind Pharma – Business segments
Exhibit 50: Mankind Pharma – Organizational developments
Exhibit 51: Mankind Pharma – Segment focus
Exhibit 52: Mankind Pharma – Key offerings
Exhibit 53: Perrigo overview
Exhibit 54: Perrigo– Business segments
Exhibit 55: Perrigo– Organizational developments
Exhibit 56: Perrigo– Geographic focus
Exhibit 57: Perrigo– Segment focus
Exhibit 58: Perrigo– Key offerings
Exhibit 59: Piramal Enterprises overview
Exhibit 60: Piramal Enterprises– Business segments
Exhibit 61: Piramal Enterprises– Organizational developments
Exhibit 62: Piramal Enterprises– Geographic focus
Exhibit 63: Piramal Enterprises– Segment focus
Exhibit 64: Piramal Enterprises– Key offerings
Exhibit 65: Sun Pharmaceutical Industries overview
Exhibit 66: Sun Pharmaceutical Industries– Business segments
Exhibit 67: Sun Pharmaceutical Industries– Organizational developments
Exhibit 68: Sun Pharmaceutical Industries– Geographic focus
Exhibit 69: Sun Pharmaceutical Industries– Segment focus
Exhibit 70: Sun Pharmaceutical Industries– Key offerings
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
‧ Market ecosystem
‧ Market characteristics
‧ Market segmentation analysis
PART 05: MARKET SIZING
‧ Market definition
‧ Market sizing 2017
‧ Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
‧ Bargaining power of buyers
‧ Bargaining power of suppliers
‧ Threat of new entrants
‧ Threat of substitutes
‧ Threat of rivalry
‧ Market condition
PART 07: MARKET SEGMENTATION BY DISTRIBUTION CHANNEL
‧ Segmentation by distribution channel
‧ Comparison by distribution channel
‧ Retail stores
‧ Online stores
‧ Market opportunity by distribution channel
PART 08: CUSTOMER LANDSCAPE
PART 09: REGIONAL LANDSCAPE
‧ Geographical segmentation
‧ Regional comparison
‧ Americas– Market size and forecast 2017-2022
‧ EMEA – Market size and forecast 2017-2022
‧ APAC – Market size and forecast 2017-2022
‧ Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
‧ Market drivers
‧ Market challenges
PART 12: MARKET TRENDS
‧ Importance of family planning
‧ Advent of online apps
‧ Rising disposable income
PART 13: VENDOR LANDSCAPE
‧ Overview
‧ Landscape disruption
PART 14: VENDOR ANALYSIS
‧ Vendors covered
‧ Vendor classification
‧ Market positioning of vendors
‧ LUPIN
‧ Mankind Pharma
‧ Perrigo
‧ Piramal Enterprises
‧ Sun Pharmaceutical Industries
PART 15: APPENDIX
‧ List of abbreviations
?
Exhibit 01: Parent market
Exhibit 02: Global female contraceptive market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global emergency contraceptive pill 2017-2022 ($ mn)
Exhibit 09: Global emergency contraceptive pill market – Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Global emergency contraceptive pill market by distribution channel – Market share 2017-2022 (%)
Exhibit 19: Comparison by distribution channel
Exhibit 20: Retail stores – Market size and forecast 2017-2022 ($ mn)
Exhibit 21: Retail stores – Year-over-year growth 2018-2022 (%)
Exhibit 22: Online stores – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Online stores – Year-over-year growth 2018-2022 (%)
Exhibit 24: Market opportunity by distribution channel
Exhibit 25: Customer landscape
Exhibit 26: Global emergency contraceptive pill market by geography – Market share 2017-2022 (%)
Exhibit 27: Regional comparison
Exhibit 28: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 30: Top three countries in Americas
Exhibit 31: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 32: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 33: Top three countries in EMEA
Exhibit 34: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 35: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 36: Top three countries in APAC
Exhibit 37: Market opportunity
Exhibit 38: Vendor landscape
Exhibit 39: Landscape disruption
Exhibit 40: Vendors covered
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: LUPIN overview
Exhibit 44: LUPIN – Business segments
Exhibit 45: LUPIN– Organizational developments
Exhibit 46: LUPIN– Geographic focus
Exhibit 47: LUPIN – Key offerings
Exhibit 48: Mankind Pharma overview
Exhibit 49: Mankind Pharma – Business segments
Exhibit 50: Mankind Pharma – Organizational developments
Exhibit 51: Mankind Pharma – Segment focus
Exhibit 52: Mankind Pharma – Key offerings
Exhibit 53: Perrigo overview
Exhibit 54: Perrigo– Business segments
Exhibit 55: Perrigo– Organizational developments
Exhibit 56: Perrigo– Geographic focus
Exhibit 57: Perrigo– Segment focus
Exhibit 58: Perrigo– Key offerings
Exhibit 59: Piramal Enterprises overview
Exhibit 60: Piramal Enterprises– Business segments
Exhibit 61: Piramal Enterprises– Organizational developments
Exhibit 62: Piramal Enterprises– Geographic focus
Exhibit 63: Piramal Enterprises– Segment focus
Exhibit 64: Piramal Enterprises– Key offerings
Exhibit 65: Sun Pharmaceutical Industries overview
Exhibit 66: Sun Pharmaceutical Industries– Business segments
Exhibit 67: Sun Pharmaceutical Industries– Organizational developments
Exhibit 68: Sun Pharmaceutical Industries– Geographic focus
Exhibit 69: Sun Pharmaceutical Industries– Segment focus
Exhibit 70: Sun Pharmaceutical Industries– Key offerings
